ImetelChat

Link: http://ir.geron.com/news-releases/news- ... imetelstat

The company has stated Q3 for full separation - and here we are, we hear nothing. Is this separation not a material event worthy of a PR? Or has it not happened? And while we’re at it, what is that very small 2nd Agreement all about, and why is it beneficial to Geron and owners? As you can see, more...

Shout out to EarFool on Yahoo for posting this https://f1000research.com/articles/8-1662 Imetelstat is highlighted in the Novel Agents section. Man I could use a bone at next week’s conference - road weary - I suspect that the full freedom from Janssen will be announced at some point next week. That...

Finally is perhaps the understatement of the century Future is bright; success of Phase III MDS I peg above 95%. (Success of the MF FDA regulatory discussions, measured solely by accelerated approval, I’d put at around 45%) The past decade is full of successes for Imetelstat (and it’s team and colla...

I don't think anyone has posted this fantastic overview from the conference / confirmation of the breakthrough data from Imetelstat presented. Imetelstat is the headline story of this conference review: https://www.emjreviews.com/hematology/congress-review/review-of-the-european-hematology-associati...

Hello J, Remember, Geron continues to have a, much smaller, deal with Janssen that continues to be in effect - it was a $5Million at signing, I believe the potential is $75 Million more plus single digits % royalties on any “product” revenues. This is a question that I am kicking myself for not aski...

Seems that every message board is filled with loathe from this meeting. If you look at the slides it tells a very different story. Change my handle from Ryan to Pollyanna I suppose :mrgreen: Even I tried to inject some magical happening that was going to happen, with thoughts of expanded cohorts for...

Dr. Feneaux was quoted in OncLive article as saying a study in higher risk MDS patients was being planned. Do we hear something of either an academic institution stepping on to do a study or a corporate collaboration to include a high risk MDS cohort in the Phase III? That would be the only thing I ...

PS - 65% lower risk of death

Imetelstat is superior to Best Available Therapy for R/R patients in MF, that can be stated unequivocally.

Thanks for posting. The statistical superiority of Imetelstat is not only clear but profound. We’re talking about over a year-and-a-half of continued life, that most key of KPI metrics. It’s not if but when Imetelstat is approved on this indication, and I suppose the when is early next year but even...

I’m really interested to get a follow-up on the “better looking data” this weekend. For MDS, improvement in TI durability would be great to see. For MF, it is intriguing that the Dr presenting is from the Moffitt Center, which is where the real world data comparator set was generated from... he trul...

Forgot to mention the intricacy of “So far, better looking data.” Considering that “So far” in this case means over a decade of preclinical and clinical successes, including near 100% CRs in ET and ‘tantamount to a cure’ in some MF cases according to the Mayo Clinic brochure, all built on a Nobel Pr...

Here are the top quotes that I wrote down to focus on. What it does not include are Dr Rizo’s brilliant answers, which were too deeply reasoned and in-depth for me to jot down, frankly. Dr. Scarlett is certainly more ‘jottable’, and here are a couple of the doozies this past Thursday: “We have a Pha...

Great updates. There really is nothing to add but, let's wait it out. I think with so many bumps in the road, as detailed by Biopearl, it's incredibly difficult to not be jaded, however cleaning the slate on history it becomes clear that Imetelstat is indeed a "soon-to-be" first-in-class drug with a...

Well I see a lot of reads on my latest post - I suppose everyone just agrees with me

4 days we know... good luck all in this dawn of the next era for Imetelstat...

Well, we have no new hints at all about what is to come on Thursday. BioPearl, I've certainly come around to your inclination, which is we'll have the release of the EMA abstract as a headliner, so to speak. Here is what I am thinking at this point- Dr. Scarlett begins the call with the news of the ...

OK, let's have some conjecture from some, inquiring minds want to know. I think we can rule out any sort of FDA provisional approval, that would be the pie in the sky, and would be an immediate release. Most likely, in my opinion, the transfer of IND from Janssen is complete. I am presuming here it ...

Hello Biopearl, That historic pps is not correct. The stock was in the $2.10-2.20 range the week Dr. Scarlett took over. It dropped further about 6 months later when he announced divestiture of stem cell program. It was high of 6 the prior year well before Dr. Okarma announced he was leaving. The ca...

Thought this would be a good bookmark for this board, for any new browsers seeking to learn more about our new leadership team at the helm for Phase III initiation and regulatory filings. Seems the perfect fits and I don't think anyone can refute that we are in a better place now than in late Septem...

Hello Mr. Shah, As I have posted on here before, I am personally against (or better word, uninterested) in activism at this juncture... Geron now holds 100% alone and can move forward with the drug as it sees fit. I am more keen on where we are going then CSI'ing Janssen/JNJ's actions and intentions...